Active substance
Oxaliplatin
- SFDA 29
- US FDA 34
- Health Canada 5
- WHO EML 1
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| BATIPAN 100 mg per 50 ml - VIAL | 2 mg/ml | Powder for solution for infusion · Intravenous use | 1 Vial | SAR 237.25 | Generic · Prescription | Boston Oncology Arabia | Valid |
| BATIPAN 50MG INJECTION | 5 mg | Powder for solution for infusion · Intravenous use | 1 Vial | SAR 118.60 | Generic · Prescription | Boston Oncology Arabia | Valid |
| ELOXATIN 100MG VIAL | 100 mg | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 1835.65 | NCE · Prescription | SANOFI AVENTIS DEUTSCHLAND GMBH | Valid |
| ELOXATIN 50MG VIAL | 50 mg | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 966.10 | NCE · Prescription | SANOFI AVENTIS DEUTSCHLAND GMBH | Valid |
| OXALIPLATIN 5MG/ML (20ml) | 5 mg/ml | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 444.35 | Generic · Prescription | Accord Healthcare Limited | Valid |
| OXALIPLATIN MEDAC 100MG POWDER | 100 mg | Powder for solution for infusion · Intravenous use | 1 Vial | SAR 773.50 | Generic · Prescription | MEDAC | Valid |
| OXALIPLATIN MEDAC 150MG POWDER | 150 mg | Powder for solution for infusion · Intravenous use | 1 Vial | SAR 1160.25 | Generic · Prescription | MEDAC | Valid |
| OXALIPLATIN MEDAC 50MG POWDER | 50 mg | Powder for solution for infusion · Intravenous use | 1 Vial | SAR 396.80 | Generic · Prescription | MEDAC | Valid |
| Oxaliplatin AqVida 100 mg per 20 ml | 5 mg/ml | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 234.75 | Generic · Prescription | AqVida GmbH | Valid |
| Oxaliplatin AqVida 200 mg per 40 ml | 5 mg/ml | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 449.30 | Generic · Prescription | AqVida GmbH | Valid |
| Oxaliplatin AqVida 50 mg per 10 ml | 5 mg/ml | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 114.90 | Generic · Prescription | AqVida GmbH | Valid |
| PLAXOTRIN 5 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION (10ml) | 5 mg/ml | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 118.60 | Generic · Prescription | GENEPHARM S.A | Valid |
| PLAXOTRIN 5 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION (20 ml) | 5 mg/ml | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 237.25 | Generic · Prescription | GENEPHARM S.A | Valid |
| XALTIN 5MG/ML CONC. FOR SOLUTION FOR INFUSION (10ml) | 5 mg/ml | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 222.15 | Generic · Prescription | Accord Healthcare Limited | Valid |
| Xaliptine | 5 mg/ml | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 234.75 | Generic · Prescription | HEXAL AG | Valid |
| Xaliptine | 5 mg/ml | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 114.90 | Generic · Prescription | HEXAL AG | Valid |
| ELOXATIN 100MG VIAL | 100 mg | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 2402.40 | NCE · Prescription | sanofi-aventis | Withdrawn by MAH · Not Marketed |
| ELOXATIN 50MG VIAL | 50 mg | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 1396.75 | NCE · Prescription | sanofi-aventis | Withdrawn by MAH · Not Marketed |
| OXALIPLATIN 5 MG-ML VIAL | 5 mg/ml | Solution for infusion · Intravenous use | 1 Vial | SAR 1458.10 | Generic · Prescription | EBEWE PHARMA | Withdrawn by MAH · Not Marketed |
| OXALIPLATIN 5 MG-ML VIAL | 5 mg/ml | Solution for infusion · Intravenous use | 1 Vial | SAR 1968.45 | Generic · Prescription | EBEWE PHARMA | Withdrawn by MAH · Not Marketed |
| OXALIPLATIN 5 MG-ML VIAL | 5 mg/ml | Solution for infusion · Intravenous use | 1 Vial | SAR 767.45 | Generic · Prescription | EBEWE PHARMA | Withdrawn by MAH · Not Marketed |
| OXALIPLATIN ACTAVIS 100 mg lyophilisate for solution for infusion | 100 mg | Solution for infusion · Intravenous use | 1 Vial | SAR 444.35 | Generic · Prescription | ACTAVIS | Withdrawn by MAH · Not Marketed |
| OXALIPLATIN ACTAVIS 50 mg lyophilisate for solution for infusion | 50 mg | Solution for infusion · Intravenous use | 1 Vial | SAR 222.15 | Generic · Prescription | ACTAVIS | Withdrawn by MAH · Not Marketed |
| OXALIPLATIN HOSPIRA 5MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION | 5 mg/ml | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 619.90 | Generic · Prescription | HOSPIRA UK LIMITED | Withdrawn by MAH · Not Marketed |
| OXALIPLATIN HOSPIRA 5MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION | 5 mg/ml | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 309.95 | Generic · Prescription | HOSPIRA UK LIMITED | Withdrawn by MAH · Not Marketed |
4 more — full table
Indications — CHI Daman Drug Formulary
ANAL CANCER; BILIARY TRACT CANCER; COLORECTAL CANCER-EARLY & ADVANCED; DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL); ESOPHAGEAL CANCER; FOLLICULAR LYMPHOMA; GASTRIC CANCER; HODGKIN'S LYMPHOMA; MALIGNANT NEOPLASM OF THE PANCREAS; MANTLE CELL LYMPHOMA; NEUROENDOCRINE TUMORS; OVARIAN CANCER; T-CELL LYMPHOMA; TESTICULAR CANCER
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| OXALIPLATIN | 50MG/10ML (5MG/ML); 100MG/20ML (5MG/ML) | injectable · intravenous | HOSPIRA WORLDWIDE | Prescription | 7 Aug 2009 |
| OXALIPLATIN | 50MG/VIAL; 100MG/VIAL | injectable · intravenous | FRESENIUS KABI USA | Prescription | 2 Jun 2010 |
| OXALIPLATIN | 50MG/10ML (5MG/ML); 100MG/20ML (5MG/ML) | injectable · intravenous | FRESENIUS KABI USA | Prescription | 10 Jun 2010 |
| OXALIPLATIN | 50MG/10ML (5MG/ML); 100MG/20ML (5MG/ML) | injectable · intravenous | SANDOZ | Prescription | 24 Jan 2011 |
| OXALIPLATIN | 50MG/10ML (5MG/ML); 100MG/20ML (5MG/ML) | injectable · intravenous | MYLAN LABS LTD | Prescription | 7 Aug 2012 |
| OXALIPLATIN | 50MG/VIAL; 100MG/VIAL | injectable · intravenous | QILU PHARM HAINAN | Prescription | 11 May 2016 |
| OXALIPLATIN | 50MG/10ML (5MG/ML); 100MG/20ML (5MG/ML); 200MG/40ML (5MG/ML) | injectable · intravenous | QILU PHARM HAINAN | Prescription | 7 Jun 2016 |
| OXALIPLATIN | 50MG/10ML (5MG/ML); 100MG/20ML (5MG/ML) | injectable · intravenous | GLAND | Prescription | 10 Feb 2017 |
| OXALIPLATIN | 50MG/10ML (5MG/ML); 100MG/20ML (5MG/ML) | injectable · intravenous | ACCORD HLTHCARE | Prescription | 21 Mar 2017 |
| OXALIPLATIN | 50MG/VIAL; 100MG/VIAL | injectable · intravenous | GLAND | Prescription | 23 May 2017 |
| OXALIPLATIN | 50MG/10ML (5MG/ML); 100MG/20ML (5MG/ML) | injectable · intravenous | MEITHEAL | Prescription | 11 Jan 2024 |
| OXALIPLATIN | 50MG/10ML (5MG/ML); 100MG/20ML (5MG/ML) | injectable · intravenous | HETERO LABS LTD VI | Prescription | 27 Jan 2025 |
| OXALIPLATIN | 50MG/10ML (5MG/ML); 100MG/20ML (5MG/ML) | injectable · intravenous | SHANDONG | Prescription | 15 Jan 2026 |
| ELOXATIN | 50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 100MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · intravenous | SANOFI AVENTIS US | Discontinued | 9 Aug 2002 |
| ELOXATIN | 50MG/10ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 100MG/20ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 200MG/40ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · intravenous | SANOFI AVENTIS US | Discontinued | 31 Jan 2005 |
| OXALIPLATIN | 50MG/VIAL; 100MG/VIAL | injectable · intravenous | FRESENIUS KABI ONCOL | Discontinued | 7 Aug 2009 |
| OXALIPLATIN | 50MG/10ML (5MG/ML); 100MG/20ML (5MG/ML) | injectable · intravenous | SANDOZ | Discontinued | 7 Aug 2009 |
| OXALIPLATIN | 50MG/VIAL; 100MG/VIAL | injectable · intravenous | SUN PHARM | Discontinued | 7 Aug 2009 |
| OXALIPLATIN | 50MG/10ML (5MG/ML); 100MG/20ML (5MG/ML) | injectable · intravenous | TEVA PHARMS | Discontinued | 7 Aug 2009 |
| OXALIPLATIN | 50MG/VIAL; 100MG/VIAL | injectable · intravenous | HOSPIRA INC | Discontinued | 30 Sep 2009 |
| OXALIPLATIN | 50MG/VIAL; 100MG/VIAL | injectable · intravenous | SANDOZ | Discontinued | 28 Apr 2011 |
| OXALIPLATIN | 200MG/40ML (5MG/ML) | injectable · intravenous | MYLAN LABS LTD | Discontinued | 7 Aug 2012 |
| OXALIPLATIN | 50MG/VIAL; 100MG/VIAL | injectable · intravenous | ACTAVIS TOTOWA | Discontinued | 8 Aug 2012 |
| OXALIPLATIN | 50MG/VIAL; 100MG/VIAL | injectable · intravenous | PHARMOBEDIENT | Discontinued | 8 Aug 2012 |
| OXALIPLATIN | 50MG/10ML (5MG/ML); 100MG/20ML (5MG/ML); 200MG/40ML (5MG/ML) | injectable · intravenous | SUN PHARM | Discontinued | 8 Apr 2014 |
9 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| OXALIPLATIN | 02444763 | 5 MG / ML | SOLUTION · INTRAVENOUS | PFIZER CANADA ULC |
| OXALIPLATIN INJECTION | 02435071 | 5 MG / ML | SOLUTION · INTRAVENOUS | TEVA CANADA LIMITED |
| OXALIPLATIN INJECTION | 02436957 | 5 MG / ML | SOLUTION · INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| OXALIPLATIN INJECTION, USP | 02457423 | 5 MG / ML | SOLUTION · INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| OXALIPLATIN INJECTION, USP | 02458403 | 5 MG / ML | SOLUTION · INTRAVENOUS | DR REDDY'S LABORATORIES LTD |
WHO WHO Model List of Essential Medicines (2025)
- 8.2.1. Cytotoxic medicines · complementary
Malignant neoplasm metastasis in large intestine; Malignant neoplasms of colon
Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial
Safety signals and safety-related labeling changes
- US FDA 31 Oct 2024 OXALIPLATIN — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 23 Jun 2023 ELOXATIN — safety-related labeling change
Labeling sections changed: Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.